The Board of the company currently consists of one executive member and six non-executive members, each of whom is considered by the Board to be independent in character and judgment. The Board performs regular reviews of its composition as to background, function and experience, in order to ensure diversity and to balance knowledge of Idorsia’s business with fresh perspectives.

Board of Directors

Mathieu Simon

Date of birth: 6 May 1956

Nationality: French

Show more

Education: Université de Paris (Paris 7)

Professional background: Former Chairman of the Board of Cellartis; EVP & COO of Cellectis Group, CEO of Cellectis Therapeutics and Ectycell; MD & Head of Global Pharma Operations at Pierre Fabre; and various management and EU regional management roles as well as senior corporate functions at Wyeth Pharmaceuticals

Other activities and functions: Member of the Affimed Supervisory Board, member of the Board of Lysogene, Asarina Pharma, BB Pureos Bioventure, and Messier Maris & Associés

Show less

Date of birth: 22 February 1959

Nationality: German

Show more

Education: Business degrees from the European Business School and Harvard Business School (Advanced Management Program)

Professional background: Chief Executive Officer of uniQure N.V., President and Chief Executive Officer of Evotec AG, and the former Chairman of the Board of Directors of Molecular Partners

Other activities and functions: CEO of HOOKIPA Pharma, and Chairman of the Board of Genespire S.r.l.

Show less

Date of birth: 3 April 1955

Nationality: Swiss and French

Show more

Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US

Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997. Founder and CEO of Actelion, 1999–2017

Other activities and functions: None

Show less

Date of birth: 18 February 1951

Nationality: French

Show more

Education: Graduate of the École des Hautes Etudes Commerciales (HEC) and the École Nationale d’Administration (ENA)

Professional background: Chairman & CEO and GM of Eutelsat; Chairman & CEO of ViroPharma; held various positions within the Rhône-Poulenc Group: GM of Pharmuka, Rhône-Poulenc Fibers & Polymers, and Chairman & CEO of Rhône Poulenc Rorer & Rhône-Poulenc Santé; and Auditor at the French Ministries of Finance and Defense

Other activities and functions: Chairman of the Board at DBV Technologies, Pharnext and Faurecia

Show less

Date of birth: 26 February 1957

Nationality: Swiss

Show more

Education: Doctorate in law from the University of Zurich, Master of Laws in Business & Taxation from the McGeorge School of Law, California and further education from Harvard Business School

Professional background: Group General Counsel and a member of the Executive Committee of Novartis, Executive Chairman of Bär & Karrer

Other activities and functions: Chairman of the Board at Globalance Bank; Board Member & Audit Committee Chair at Geberit; member of the Board of Hyos Investment Holding AG and Swiss Fintech AG. Board Member of the Law and Economics Foundation at University of St. Gallen and of the UZH Foundation at University of Zurich

Show less

Date of birth: 24 January 1965

Nationality: American

Show more

Education: Master of Laws degrees from Cornell University & New York University, and is a member of the New York State Bar

Professional background: Chief Financial Officer and Chief Business Officer at Sarepta Therapeutics, SVP at Celgene, held senior roles in business development & tax at Pfizer and begun his career at Ernst & Young

Other activities and functions: Chairman of the Board at Aeglea BioTherapeutics and Flexion Therapeutics as well as President, COO and CFO of National Resilience Inc

Show less

Date of birth: 15 October 1963

Nationality: French

Show more

Education: MBA, Ecole Supérieure de Commerce de Paris

Professional background: Held various executive positions such as Head of Finance and Control NBE at Nestlé, Group CFO of Galderma, Global Pharma Business unit CFO and EMEA CFO at Wyeth, Global Division CFO at Novartis OTC

Other activities and functions: Member of the Board of Directors of UCB, DBV Technologies, Voluntis SA and Novo Holdings

Show less

Elections and Terms of Office

Under Articles 13 and 16 of the Articles of Association, the 3–9 members of the Board of Directors are elected individually by the General Meeting of the Shareholders for a term of office corresponding to the legally permitted maximum term of one year. One year of office is understood to be the period from one ordinary Meeting of the Shareholders to the next ordinary Meeting of the Shareholders.

Time of First Election and Remaining Term of Office

  Executive
Member
Date of AGM of first election Date of AGM of end of term
Mathieu Simon No 2019 2021
Joern Aldag No 2020 2021
Jean-Paul Clozel Yes 2017 2021
Michel de Rosen No 2020 2021
Felix R. Ehrat No 2020 2021
Sandy Mahatme No 2020 2021
Viviane Monges No 2018 2021